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Abstract
Background: L1 cell adhesion molecule (L1CAM) overexpression has been reported to be strongly associated with
poor prognosis in early stage endometrial cancer (EC).
We aimed at the validation of L1CAM as a marker of poor prognosis in an independent study population.
Methods: Patients with endometrioid EC FIGO stage I, were treated at Oslo University Hospital between 2005 and
2012. L1CAM expression was detected by immunohistochemistry with >10 % L1CAM staining defined as positive.
Risks of relapse and death were estimated as hazard ratios (HRs) with 95 % confidence intervals (95 % CI).
Results: Of 450 patients, 388 (86 %) were evaluable for L1CAM expression and 35 (9 %) were L1CAM positive. After
follow-up for a median time of 4.8 years (0.1–8.8), 33 (8 %) patients had recurred. 6/35 (17 %) L1CAM positive
patients relapsed compared to 27/353 (8 %) L1CAM-negative patients. There were 7 (20 %) deaths in the L1CAM
positive group, and 34 (10 %) in the negative group. In multivariate analysis, controlled for age and FIGO stage,
L1CAM positivity was not significantly associated with the risk of relapse (HR 2.08, 95 % CI: 0.85–5.10, p = 0.11) or
death of all-cause (HR 1.81, 95 % CI: 0.79–4.11, p = 0.16). In patients who were not treated with chemotherapy,
L1CAM was significantly associated with risk of relapse (HR 2.9; 95 % CI: 1.08–7.56; p = 0.04).
Conclusion: Our report confirms that L1CAM is associated with a more aggressive tumortype and more distant
relapses. The overall recurrence rate in this population was low as were the absolute differences between L1CAM
positive and negative patients. In this independent study sample, L1CAM failed to be a clinically relevant marker of
poor prognosis in stage I endometrioid endometrial carcinoma.
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Background
Endometrial cancer (EC) is the most common malignancy
in the female genital tract in the Western world, and the
fourth most common cancer in women after breast, lung
and colorectal cancer. Two different clinicopathological
subtypes of EC are recognized, the estrogen-related (type
I) endometrioid adenocarcinoma, and the non-estrogen
related (type II) non-endometrioid, mostly serous adeno-
carcinoma [1]. Endometrioid adenocarcinomas represent
80 % of endometrial carcinomas and patients are often
diagnosed at an early stage with disease localized to the
uterus [1]. These patients will have a favourable prognosis
with five-year overall survival rates of up to 85 %. Despite
the overall good prognosis some patients will eventually
relapse and may ultimately die of the disease. The most
important prognostic factors in stage I disease are age,
grade of differentiation, myometrial invasion, lymphovas-
cular space invasion (LVSI) and histological type. Trad-
itionally these risk factors have been used to categorize
patients into risk groups and to tailor adjuvant treatment.
The current clinical challenge is to identify patients at
high risk for distant relapse as they have a substantially
worse prognosis.
Recently, L1 cell adhesion molecule (L1CAM) has
been suggested as a biomarker that may discriminate a
subset of highly aggressive tumors with adverse clinical
outcome [2, 3]. L1CAM belongs to the immunoglobulin
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(Ig) supergene family and is a transmembrane glyco-
protein of 200–220 kDA. This cell adhesion molecule
plays an important role in nervous system development,
including neuronal migration, and differentiation. In endo-
metrial cancer, L1CAM staining has been described as dif-
fuse and localized in tumor cells adjacent to the stroma,
suggestive of the role of L1CAM in the migration and in-
vasion of tumor cells [4]. Retrospective studies have shown
that L1CAM expression in even small areas of endome-
trioid adenocarcinomas is associated with adverse out-
come [2, 3, 5]. Zeimet et al. included stage I endometrioid
endometrial carcinoma only and reported 17.7 % L1CAM
positive tumors [3]. L1CAM positivity was associated with
increased risk of relapse, especially distant relapse, and risk
of death. More recently, these findings were confirmed in
an analysis of L1CAM expression in endometrial cancers
from two randomised controlled trials (PORTEC-1 and
-2) [2] and in a multicentre retrospective study conducted
by the ENITEC consortium [6]. However, the prevalence
of 7 % positive tumors was substantially lower compared
to the initial report.
The aim of this study was to analyse L1CAM expres-
sion in an independent series of stage I endometrioid
endometrial carcinoma and to study the association of
L1CAM expression with risk of relapse and death.
Methods
Patients and follow-up
Patients were selected from a validated quality assurance
database at the Department of Gynecological Cancer at
the Oslo University Hospital. The database covers all
patients treated at Oslo University Hospital (The Norwe-
gian Radium Hospital, Ullevål University Hospital and
Rikshospitalet) for endometrial cancer. The database is
linked to Statistics Norway and individual survival data
are available through this linkage. The database provides
detailed information on the primary diagnosis, the
preoperative work-up, comorbidity, surgical treatment,
adjuvant treatment, incident relapse, localization of re-
lapse, and date of death. We included all patients with
endometrioid endometrial cancer stage I, treated at
the Oslo University Hospital between 2005 and 2012.
Histopathological diagnosis was confirmed by review
of the hematoxylin-eosin slides by three surgical pa-
thologists (BD, BR, BK) specialized in gynecologic
pathology at the Norwegian Radium Hospital. Patients
with synchronous ovarian cancer were excluded (n = 33).
For this study the optimal slide from each individual case
was selected, based on the presence of sufficient amount
of tumor, good fixation and the presence of normal myo-
metrium as a control.
Patients were staged according to the 2009 FIGO
classification and categorized as low (stage IA, grade 1
and 2), intermediate (stage IA grade 3, or stage IB
grade 1 and 2), or high risk (stage IB grade 3). They
were treated with surgery and adjuvant chemotherapy
according to the national treatment policy. In general,
low risk patients were treated with extrafascial hyster-
ectomy and bilateral salpingo-oophorectomy alone,
while intermediate and high-risk patients underwent
lymph node staging. After surgery, high-risk patient
were offered systemic treatment with platinum-based
chemotherapy. Patients were followed every 3 months
for the first 2 years and every 6 months for the next 3
years. Visits included thorough clinical examination
and vaginal ultrasound, supplemented by CT or MR
scan on clinical indication.
Immunohistochemical staining and evaluation of
expression
The formalin fixed paraffin-embedded (FFPE) tissue blocks
were collected and cut into 3-4μm sections and mounted
on Superfrost slides. The sections were analyzed for
L1CAM protein expression using the Dako FLEX+
protocol (Dako, Glostrup, Denmark). The L1CAM anti-
body was a mouse monoclonal antibody (clone 14.10,
cat. # SIG-3911) from Covance (Princeton NJ), applied
at 1:300 dilutions. Antigen retrieval was performed in
low pH buffer (Dako). Visualization was achieved using
3′3-diaminobenzidine tetrahydrochloride substrate (DAB)
and hematoxylin counterstaining. Positive control con-
sisted of a high-grade serous carcinoma shown to be
positive in antibody testing, and was satisfactory in all
reactions. Negative controls consisted of slides stained
with IgG1k murine melanoma immunoglobulin (Sigma-
Aldrich, St. Louis MO; cat. # M9035) at the same
concentration.
Staining extent was scored as positive (>10 % of cells)
(Fig. 1) vs. negative (≤10 % of cells). This cut-off has pre-
viously been reported to result in the strongest model
and was confirmed by Bosse et al. [2, 3]. Scoring was
performed by one gynecologic pathologist (BD), which
was blinded for clinical outcome.
Statistical analysis
This study is a ”prospective-retrospective” design that
used archived tumor specimen as suggested by Simon et
al. [4]. Our power calculation was based on results re-
ported in the literature. Relapse rates of 3 % in L1CAM
negative tumors and 50 % in L1CAM positive tumors
have been reported [3]. Given a statistical power of 80 %
and alpha of 5 % we would have needed 17 patients in
each group and 10 relapses in total. Further, an absolute
difference of 37 % in the number of deaths has been
reported previously [3], with 40 % death rate in the
L1CAM positive group and 3 % death rate in the nega-
tive group. With the same statistical assumptions as
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above (HR = 3), we would have needed 24 patients in
each group and 10 deaths to replicate the results. There-
fore, given the sample size available and the above stated
assumptions, our study was sufficiently powered.
Continuous variables were descried as median and
range. Categorical variables were presented with counts
and proportions. Crude associations between L1CAM
negative and L1CAM positive patients and categorical
variables were assessed with χ2 test.
When studying the risk of relapse, follow-up time was
calculated from the date of EC diagnosis until date of
relapse, date of death from any cause or end of follow-
up, August 31, 2014, whichever occurred first.
For risk of death, follow-up time was calculated from
the date of EC diagnosis until date of death from any
cause or end of follow-up, whichever occurred first.
Survival curves were plotted with the Kaplan-Meier
method. The log rank test was used to compare survival
between the groups. Crude hazard ratios (HRs) of
relapse and death with 95 % confidence intervals (CI) as-
sociated with L1CAM overexpression were calculated
using Cox proportional hazard models. The proportion-
ality assumption was tested using Schoenfeld’s residuals.
All variables revealing prognostic significance in the
univariate analysis or previously have been reported to
be associated with risk of relapse or death, were included
in the multivariable model. The final multivariate model
was adjusted for FIGO stage and age < vs ≥ 60 years. An
alternative model was adjusted for age as attained age at
the diagnosis of endometrial cancer and contained
L1CAM status, FIGO stage and grade. However the
estimates remained unchanged. In exploratory subgroup
analysis by treatment with adjuvant chemotherapy or
not, we studied the association of L1CAM expression
with the risk of relapse. P-values <0.05 were considered
statistically significant and all tests were two-sided.
The analyses were performed using IBM SPSS version
22 (SPSS, Chicago, IL) and the STATA statistical pack-
age, version 11.0, (Stata Corp LP, Texas, USA).
Results
Patient and characteristics and treatment
During our study period, 450 patients underwent sur-
gery for FIGO stage I endometrioid endometrial adeno-
carcinomas. In 62 patients (14 %) the amount of tumor
tissue archived was insufficient, the material had under-
gone autolysis or we did not obtain informed consent. In
total, 388 (86 %) were evaluable for the L1CAM expres-
sion (Fig. 2). The median age of the study population at
diagnosis was 66.8 years (range 39–91 years) and median
follow-up time was 4.8 years (range 0.1–8.8). Baseline
characteristics of the study population are displayed in
Table 1. Of the total cohort, 186 (48 %) patients had
undergone pelvic lymphadenectomy and of these 107
(28 %) also had para-aortic lymphadenectomy. The
majority of patients, 350 (90 %) received no adjuvant
treatment, while 38 (10 %) patients received adjuvant
chemotherapy and one patient underwent postoperative
pelvic radiotherapy.
L1CAM expression
Of the 388 cases available for immunohistochemical stain-
ing, 35 (9 %) stained positive for L1CAM, and 353 (91 %)
were L1CAM negative. In 5 cases L1CAM expression was
observed in 5–10 % of the cells. These were not consid-
ered as positive cases in the analysis.
Fig. 1 Immunohistochemical staining of L1CAM positive tumor
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L1CAM positivity was strongly associated with histo-
logical differentiation (p < 0.001), with an increasing
proportion of L1CAM positive tumors with poorer differ-
entiation. L1CAM positivity was also strongly associated
with increasing risk grouping (p < 0.001). A significantly
higher proportion of L1CAM positive patients had under-
gone pelvic lymphadenectomy (23/35 = 66 % vs 163/353 =
46 %, p = 0.027) or had received adjuvant chemotherapy
(12/35 = 34 % vs 26/353 = 7 %, p < 0.001). L1CAM positive
patients were slightly older compared to L1CAM negative
patients, with a median age of 70.6 years (range 47.8–88.8)
and 66.5 years (range 38.8–91.2), respectively, however, this
difference was not statistically significant. There were no
significant associations between L1CAM expression and
FIGO stage, lymphovascular space invasion (LVSI), dia-
betes, smoking, or obesity as defined by BMI ≥30 kg/m2.
Relapse and death
A total of 33 patients (8.5 %) recurred during follow-up
(Table 2) and 29 of those had not received adjuvant
chemotherapy. In the L1CAM positive group, half the
relapses were isolated vaginal relapses and half were
distant metastasis. In the L1CAM negative group, most
relapses were isolated vaginal relapses and only 1 %
recurred with distant metastasis. Median disease-free
survival was not reached (Fig. 3). In subgroup analysis
for adjuvant chemotherapy, 24 out of 327 L1CAM nega-
tive patients relapsed after no adjuvant chemotherapy
compared to 5 out of 23 L1CAM positive patients. The
distribution of relapses in those patients was similar to
the cohort as a whole with more distant relapses in the
L1CAM positive group (Table 3).
In univariate analysis on the total group of patients,
L1CAM positivity was not significantly associated with
disease free survival (HR: 2.38, 95 % CI 0.98–5.77, p = 0.06),
neither were FIGO stage nor age. In multivariate analysis,
L1CAM positivity was not significantly associated with dis-
ease free survival (HR 2.08; 95 % CI: 0.85–5.10, p = 0.11)
(Table 4).
In the subgroup that did not receive adjuvant chemo-
therapy, L1CAM positivity was significantly associated
with disease free survival in univariate analysis (HR 3.2,
CI: 1.24–8.56, p = 0.02). This significance was maintained
when we controlled for age and stage (HR 2.9; 95 % CI:
1.08–7.56; p = 0.04). In patients who had received adjuvant
chemotherapy, there was no such association (HR 0.68;
95 % CI: 0.07–6.76, p = 0.74).
In total, 41 patients died during follow-up. There were
seven deaths (20.0 %) in the L1CAM positive group, and
34 deaths (9.6 %) in the negative group (p = 0.057)
(Table 2). Median overall survival was not reached (data
not shown). For the total group, L1CAM expression was
not significantly associated with risk of death. FIGO
stage and age were the only prognostic factors signifi-
cantly associated with risk of death in univariate analysis
(data not shown). The association with L1CAM expres-
sion remained non-significant, also in multivariate analysis
(HR 1.81; 95 % CI: 0.79–4.11, p = 0.16) (Table 4).
Discussion
This study aimed at the validation of L1CAM as marker of
poor disease-free and overall survival in early stage endo-
metrial cancer. The overall recurrence rate was low with
only 9 % recurrences in the cohort as a whole and 17 %
in L1CAM positive tumors. In the total cohort, neither
disease-free nor overall survival differed significantly
between L1CAM positive and negative patients when
controlled for other prognostic factors. In a subgroup
analysis of patients who had not received adjuvant
chemotherapy, we found L1CAM expression significantly
associated with disease free survival.
Fig. 2 Study population
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Several potential biases of retrospective studies were
avoided as we a priori defined inclusion and exclusion
criteria for the study sample. We also used the same
immunohistochemical methods and a validated cut-off
of 10 % for L1CAM positivity as described in the first
report [3]. All cases underwent pathological review and
were confirmed endometrioid adenocarcinomas. Surgical
and adjuvant treatment were however defined by insti-
tutional guidelines and differed considerably between
L1CAM positive and negative tumors. The differential
Table 1 Baseline characteristics according to L1CAM status (n = 388)





Age at diagnosis 0.116
< 60 111 28,6 6 17,1 105 29,7
> 60 277 71,4 29 82,9 248 70,3
FIGO stage 0.223
1A 268 69,1 21 60,0 247 70,0
1B 120 30,9 14 40,0 106 30,0
Risk Groups <0.001
Low 238 61,3 14 40,0 224 63,5
Intermediate 120 30,9 13 37,1 107 30,3
High 27 7,0 8 22,9 19 5,4
Grading <0.001
Grade I 231 59,5 9 25,7 222 62,9
Grade II 103 26,5 11 31,4 92 26,1
Grade III 54 13,9 15 42,9 39 11,0
LVSI 371 35 336 0.756
Yes 61 16,4 7 20,0 54 16,1
No 268 72,2 25 71,4 243 72,3
Unknown 42 11,3 3 8,6 39 11,6
Pelvic lymphadenectomy 0.016
No 202 52,1 12 34,3 190 53,8
Yes 186 47,9 23 65,7 163 46,2
Para-aortic lymphadenectomy 0.082
No 281 72,4 20 57,1 261 73,9
Yes 107 27,6 15 42,9 92 26,1
Adjuvant chemotherapy 35 353 <0.001
No 350 90,2 23 65,7 327 92,6
Yes 38 9,8 12 34,3 26 7,4
Diabetes 35 353 0.102
No 325 83,8 30 85,7 295 83,6
Yes 61 15,7 4 11,4 57 16,1
Unknown 2 0,5 1 2,9 1 0,3
Obesity 375 34 341 0.127
BMI < 30 242 64,5 26 76,5 216 63,3
BMI > 30 133 35,5 8 23,5 125 36,7
Smoking 386 35 351 0.858
No 253 65,5 24 68,6 228 65,0
Yes 56 14,5 4 11,4 52 14,8
Unknown 77 19,9 7 20,0 70 19,9
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impact of L1CAM expression in low, intermediate, and
high-risk groups could not be analyzed in our study
due to limited power.
The prevalence of L1CAM positive tumors in our
study is lower than reported initially, but in line with the
more recent reports from PORTEC and ENITEC [2, 6].
Our study confirmed that L1CAM expression of the
tumor is associated with poor differentiation and pa-
tients with L1CAM positive tumors were more likely to
belong to groups of higher risk of relapse. The associ-
ation between L1CAM expression and higher grade has
also been shown by two recent reports including endo-
metrial cancer of various histologies and stages [7, 8]. In
our study, differences in risk profile between L1CAM
positive and negative patients led to considerable varia-
tions in the surgical and adjuvant treatment between the
two groups. Also, as treatment was determined by insti-
tutional guidelines, treatment differed to some extent
between the studies published to date. This is not unex-
pected as there is no overall agreement on the treatment
of early stage endometrial cancer, but this makes it chal-
lenging to compare the reported outcomes. The large vari-
ations with regard to the practice of lymphadenectomy
and the type of adjuvant treatment given are of particular
importance here. At the Oslo University Hospital, pelvic
and para-aortic lymphadenectomy is considered to be
standard treatment for patients belonging to the inter-
mediate and high-risk group. Consequently, 48 % of all
women in our cohort had undergone at least pelvic
lymphadenectomy. In the pooled analysis of PORTEC,
crude rates of lymphadenectomy in the cohort as a whole
and by L1CAM status have not been reported. However,
systematic lymphadenectomy was conducted at the sur-
geon’s discretion in the PORTEC studies, and we may
therefore assume that rates were lower than those re-
ported here and by Zeimet et al. The ENITEC study has
so far not reported on the primary surgical and adjuvant
treatment and relative risks of relapse and death were
given for all tumors in the study, including type II and
more advanced stages of endometrial cancer. Even though
it is still uncertain whether lymphadenectomy in itself
confers a benefit in survival in early stage endometrial
cancer, it may certainly lead to the upstaging of some
patients. Our population of L1CAM positive tumors may
therefore contain a higher proportion of true stage I pa-
tients while the study populations of both the other stud-
ies may have contained more patients with undetected
lymph node metastasis who generally confer a higher risk
of relapse, especially distant relapse. The fact that only 2 %
of the patients in our cohort presented with distant relapse
compared to 8 % in Zeimet et al. confirms this hypothesis.
Another factor explaining the lower HR for disease free
survival found in our study may be the use of adjuvant
chemotherapy to high-risk patients in our study.
High-risk early stage endometrial cancers were mainly
treated with adjuvant radiation therapy (VBT +/- EBRT)
in both published studies to date. Only 3 % of the L1CAM
Table 2 Clinical outcome according to L1CAM expression
(n = 388)
Event L1CAM positive
n = 35 (%)
L1CAM negative
n = 353 (%)
Total
n = 388 (%)
Relapse 6 (17) 27 (8) 33 (9)
Isolated vagina 3 (9) 18 (5) 21 (5)
Pelvic 0 4 (1) 4 (1)
Distant 3 (9) 5 (1) 8 (2)
Death 7 (20) 34 (10) 41 (11)
Fig. 3 Disease-free survival by L1CAM expression
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positive patients and 2 % of the L1CAM negative patients
had received adjuvant chemotherapy in the Austrian co-
hort [3] compared to 34 % and 7 % in our cohort, respect-
ively. In the PORTEC studies, adjuvant chemotherapy was
not given at all. Chemotherapy has been shown to de-
crease the risk of distant relapse compared to radiotherapy
and there is also evidence for better disease specific sur-
vival after chemotherapy when added to radiation [9, 10].
In the group of patients not receiving adjuvant chemother-
apy, we found a statistically significant HR of 2.9. This is
in agreement with the previous studies showing that posi-
tive staining for L1CAM is related to an increased risk of
relapse. However, these results have to be interpreted with
caution as the number of relapses in the population as a
whole was low compared to the other studies. The routine
administration of adjuvant chemotherapy to patients in
the high-risk group may have diluted the prognostic effect
of L1CAM staining for the total group of patients in
our study. The absolute differences in relapse between
L1CAM positive and negative patients were small inde-
pendent of the treatment with adjuvant chemotherapy
or not, and the proportion of patients with distant re-
lapse in L1CAM positive tumors when not given adju-
vant chemotherapy was similar to the cohort as a
whole. The clinical impact of the significant association
between L1CAM expression and relapse free survival
for patients who were not treated with chemotherapy
warrants further investigation. Prospective studies may
be needed to elucidate the value of L1CAM in predict-
ing distant metastasis and to further investigate the ef-
fect of chemotherapy in patients with L1CAM positive
tumors.
In our study, consisting mainly of patients belonging
to the low and intermediate risk group, where patients
in the intermediate group routinely underwent lymph
node staging, the absolute differences in clinical outcome
between patients with L1CAM positive and negative tu-
mors was smaller than initially assumed. This is important
as the overall risk of relapse and disease-specific death in
this population is low and the differences may not justify
more aggressive treatment of patients with L1CAM tu-
mors at this stage. Systemic adjuvant treatment of all pa-
tients with L1CAM positive tumors would be a substantial
overtreatment. It is further uncertain, whether L1CAM
status can reliably be evaluated pre-operatively as only the
pre-operative assessment of a prognostic maker would
allow tailoring of surgical treatment.
Conclusions
Our report confirms that L1CAM is associated with a
more aggressive tumortype and more distant relapses.
However, in this cohort of predominantly low risk early
stage endometrioid cancer, the overall risk of relapse and
disease-specific death is low and patients at higher risk
were treated accordingly based on histopathology. There-
fore, L1CAM staining did not seem to be a clinically rele-
vant marker of poor prognosis and indicator for further
treatment in this study.
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